Faculty

Roger S. McIntyre, MD, FRCPC Professor of Psychiatry and Pharmacology University of Toronto Chairman and Executive Director, Brain and Cognition Discovery Foundation (BCDF) Head, Mood Disorders Psychopharmacology Unit University Health Network Toronto, Canada Director, Depression and Bipolar Support Alliance (DBSA) Chicago, IL Professor and Nanshan Scholar, Guangzhou Medical University Guangzhou, China Adjunct Professor College of Medicine, Korea University Seoul, Republic of Korea

Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra Northwell School of Medicine Hempstead, NY Investigator, Center for Psychiatric Neuroscience Feinstein Institute for Medical Research Manhasset, NY Medical Director, Recognition and Prevention (RAP) Program The Zucker Hillside Hospital, Department of Psychiatry Glen Oaks, NY

Statement of Need

Bipolar I depression is a serious, debilitating disorder, and the challenge of management is compounded by the limited treatment options that are available. Current D2-targeted strategies to manage bipolar depression are limited in their effectiveness, as these approaches do not specifically target the neurobiology of the disease.

Data is emerging that demonstrates that the novel treatment strategies that target D3 receptors have shown significant clinical benefit in reducing symptom burden and improving quality of life in patients with bipolar I depression.

This CME Outfitters Snack features a faculty-guided interactive 3-D model animation that examines how D3 receptors relate to the pathogenesis of the bipolar I depression, and subsequently, how D3-targeted therapies exert their beneficial effects in promoting symptomatic remission and functional recovery.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate the role of dopamine D3 receptor function in the pathogenesis of bipolar I depression.
• Analyze the current standards of care for bipolar I depression and their limitations in achieving ideal outcomes.
• Incorporate recent clinical trial data on novel therapies with unique MOAs to achieve optimal clinical outcomes in bipolar I depression.

Financial Support

Supported by an educational grant from Allergan.

Target Audience

Psychiatrists, primary care physicians, physician assistants, and nurse practitioners who treat patients with bipolar I depression.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

AANP Credit (American Association of Nurse Practitioners):
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19043698. This activity was planned in accordance with AANP Accreditation Standards and Policies.

AAPA Credit (American Academy of PA's):
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid for one year from 05/24/19. PAs should only claim credit commensurate with the extent of their participation.

Note to ABPN Diplomates: ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy/.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. McIntyre reports that he receives grants from CIHR/GACD/Chinese National Natural Research Foundation; and Stanley Medical Research Institute. He receives research support from CIHR/GACD/Chinese National Research Foundation; and Stanley Medical Research Institute. He is on the speakers bureau for Allergan; Janssen Pharmaceutical, Inc.; Lundbeck Canada Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka Canada Pharmaceutical Inc.; Pfizer Inc.; Purdue Pharma Canada; Shire Pharma Canada ULC; Sunovion Pharmaceuticals Canada Inc.; and Takeda Pharmaceutical Company Limited.

Dr. Correll reports that he receives grants and research support from Janssen Pharmaceutical, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Alkermes; Allergan; Angelini Pharma Inc.; Boehringer-Ingelheim; Gedeon Richter; Gerson Lehrman Group, Inc.; Indivior; IntraCellular Therapies; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase, Inc.; Neurocrine Biosciences, Inc.; Novel Pharmaceuticals, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovian Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceutical Industries Ltd. He is a stock shareholder (directly purchased) of Janssen Pharmaceutical, Inc.; and Otsuka America Pharmaceutical, Inc. He provides expert testimony for Bristol-Myers Squibb Company. He is a Data Safety Monitoring Board Member/Chair for Boehringer-Ingelheim; Lundbeck; Rovi; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, Rph (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

SN-108-053119-03